Floatz logo

CANDESARTAN

Hypertensive Disorder

Augusta UniversitySmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Hypertensive Disorder cohort.

Asset / SponsorPhaseRating
VALSARTAN
University of Alabama at Birmingham
Phase 4BBB
Hydrochlorothiazide
University of Kansas Medical Center
Phase 4BBB
AMLODIPINE
Jing Liu
Phase 4BBB
Losartan
Rong Zhang
Phase 4BBB
Trandolapril
University of Florida
Phase 4BBB

View all 50 →

Same molecule, other indications

CANDESARTAN is also rated in:

stroke disorderDormant
BB
Indicative · Phase 4
68 / 100
View asset →
cardiovascular disorderDormant
BB
Indicative · Phase 4
67 / 100
View asset →
migraine disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →